Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2022
Reporting Period: Third Quarter ended September 30, 2022
Context: The registrant is an emerging growth company incorporated in Delaware. This filing announces the release of Q3 2022 results of operations and financial condition via a press release (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).
Key Financial Metrics
The provided Form 8-K text serves as a notification of the release of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the third quarter of 2022 have been issued.
Guidance, Outlook, and Risks
- Management Commentary: The company released an updated investor presentation intended for use in meetings with investors.
- Legal Disclaimer: The information furnished under Item 2.02 and Item 7.01, including the press release and investor presentation, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
- Guidance/Risks: No specific forward-looking guidance, risk factors, or contingencies are detailed in the body of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Investor Presentation) for updated operational milestones, pipeline progress, and cash runway projections.
- Verify the company's status as an emerging growth company and any implications for financial reporting standards.
- Confirm the trading symbol RXRX on the Nasdaq Global Select Market.